<DOC>
	<DOCNO>NCT01385787</DOCNO>
	<brief_summary>This non-therapeutic study . Pediatric AML patient undergo HCT myeloablative preparative regimen may enrol . Subjects enrol 10-40 day prior HCT . Three sample MRD ( measure WT1 PCR flow cytometry ) collect peripheral blood bone marrow : 1 ) pre-HCT ( &lt; 3 week prior start preparative regimen ) , 2 ) day 42 +/- 14 day post HCT ( early post-engraftment ) , 3 ) day 100 ( +/-20 day ) post HCT . For two year transplant , subject 's follow-up data collect use Research Level Forms CIBMTR Forms Net internet data entry system . The main objective determine whether association level pre-transplant post-transplant bone marrow MRD use WT1 flow cytometry 2-year event-free-survival , estimate strength association term predictive accuracy MRD . The investigator hypothesize measurable MRD either time point associate decreased 2-year event-free survival .</brief_summary>
	<brief_title>MRD Testing Before After Hematopoietic Cell Transplantation Pediatric Acute Myeloid Leukemia</brief_title>
	<detailed_description>This prospective , non-therapeutic study , assess significance minimal residual disease ( MRD ) three different time point relation allogeneic HCT pediatric AML . The study collaboration Pediatric Blood Marrow Transplant Consortium ( PBMTC ) Resource Clinical Investigations Blood Marrow Transplantation ( RCI-BMT ) Center International Blood Marrow Transplant Research ( CIBMTR ) . The study enroll pediatric AML patient undergo myeloablative HCT PBMTC sit . The eligibility criterion non-therapeutic study mirror widely accept criterion allogeneic HCT pediatric AML . The study test hypothesis assessment pre-transplant post-transplant MRD predict 2-year outcome follow transplant . Two MRD methodology study : flow cytometry WT1 PCR . The secondary hypothesis combine 2 methodology improve accuracy predict 2-year outcome follow transplant . It well establish level minimal residual disease ( MRD ) chemotherapy strong predictor relapse child acute lymphoblastic leukemia ( ALL ) [ 33 , 34 ] . Within population , MRD level potential predict patient respond well standard therapy , thus allow clinician tailor therapy minimize toxicity ensure maximal cure rate [ 10 ] . MRD level allogeneic hematopoietic stem cell transplantation ( HCT ) also predict risk relapse post-HCT [ 25 ] , lead clinical practice reduce MRD level much possible transplant . By contrast , child acute myeloid leukemia ( AML ) , prognostic value MRD level prior HCT remain unclear . Our long-term objective improve cure rate child AML . The investigator hypothesize MRD level HCT provide powerful tool select best candidate transplant , guide decision make stem cell source preparative therapy , optimize timing transplant . Measurements MRD post-HCT allow inform decision withdrawal immunosuppressive therapy , administration donor lymphocyte infusion , alternative targeted therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Subject legal guardian understand voluntarily sign informed consent . 2 . Age 021 time transplant . 3 . Karnofsky score ≥ 70 % ( age ≥ 16 year old ) , Lansky score ≥ 70 % ( age &lt; 16 year old ) . 4 . Patients adequate physical function measure : Cardiac : Left ventricular ejection fraction rest must &gt; 40 % , shorten fraction &gt; 26 % Hepatic : Bilirubin ≤ 2.5 mg/dL ; ALT , AST Alkaline Phosphatase≤ 5 x ULN Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 70 mL/min/1.73 m2 . Pulmonary : DLCO , FEV1 , FVC ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation &gt; 92 % room air . 5 . Acute myelogenous leukemia ( AML ) follow stage : High risk first complete remission ( CR1 ) , define : Having precede myelodysplasia ( MDS ) Diagnostic high risk karyotype : del ( 5q ) 5 , 7 , abn ( 3q ) , ( 6 ; 9 ) , abnormalities 12 , ( 9:22 ) , complex karyotype ( ≥3 abnormality ) , presence high FLT3 ITDAR ( &gt; 0.4 ) Having &gt; 15 % bone marrow blast 1st cycle and/or &gt; 5 % 2nd cycle achieve CR &lt; 5 % blast bone marrow , peripheral ANC &gt; 500 Intermediate risk first complete remission ( CR1 ) , define : Diagnostic karyotype neither highrisk ( define ) low risk ( inv ( 16 ) /t ( 16:16 ) ; ( 8 ; 21 ) ; ( 15 ; 17 ) ) . Included case cytogenetics could perform . &lt; 5 % blast bone marrow , peripheral ANC &gt; 500 High risk base upon COG AAML 1031 criterion : High allelic ratio FLT3/ITD+ , monosomy 7 , del ( 5q ) MRD status standard risk cytogenetics positive MRD end Induction I . &lt; 5 % blast bone marrow , peripheral ANC &gt; 500 Second great CR &lt; 5 % blast bone marrow , peripheral ANC &gt; 500 Therapyrelated AML stage Prior malignancy remission &gt; 12 month . &lt; 5 % blast bone marrow , peripheral ANC &gt; 500 6 . Myeloablative preparative regimen , define regimen include one follow backbone agent* : Busulfan ≥ 9mg/kg total dose ( IV PO ) . PKbased dosing allow , intent myeloablative dosing OR Total Body Irradiation≥1200cGy fractionate OR Treosulfan ≥ 42g/m2 total dose IV *Regimens may include secondary agent , limited AraC , Fludarabine , VP16 . Regimens combine Busulfan TBI treosulfan TBI allow long Busulfan treosulfan meet exceed dose list TBI dose list . 7 . Graft source : HLAidentical sibling PBSC , BM , cord blood Adult relate unrelated donor PBSC BM match allelic level HLAA , HLAB , HLAC , HLADRB1 great single antigen mismatch . One two unrelated cord blood unit : HLA≥4:6 low resolution level HLAA , HLAB , high resolution level HLADRB1 one unit . If one unit , must TNC≥2.5x107/kg ; two unit , combination two must TNC≥2.5x107/kg 1 . Women pregnant ( positive HCG ) breastfeeding . 2 . Evidence HIV infection HIV positive serology . 3 . Positive viral load ( PCR ) Hepatitis B C ( negative serology , surface antigen , core antibody may substitute PCR ) . 4 . Current uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) . 5 . Autologous transplant &lt; 12 month prior enrollment . 6 . Prior allogeneic hematopoietic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pediatric ( age 0-21 year )</keyword>
	<keyword>myeloablative HCT</keyword>
	<keyword>PBMTC site</keyword>
</DOC>